---
title: "Edgewise Therapeutics Says Believes Atrial Fibrillation Not Driven by EDG-7500 in Phase 2 Trial, RBC Says"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/234481163.md"
description: "Edgewise Therapeutics believes that the atrial fibrillation cases in its phase 2 trial are not linked to EDG-7500, according to RBC Capital Markets. The trial showed positive results for EDG-7500 in treating hypertrophic cardiomyopathy, with mild to moderate adverse events reported. RBC acknowledges a potential risk of drug-related atrial fibrillation but expects future data to clarify this. The firm maintains an outperform rating but lowered the price target from $56 to $52, with shares dropping over 12% recently."
datetime: "2025-04-03T16:36:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/234481163.md)
  - [en](https://longbridge.com/en/news/234481163.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/234481163.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/234481163.md) | [English](https://longbridge.com/en/news/234481163.md)


# Edgewise Therapeutics Says Believes Atrial Fibrillation Not Driven by EDG-7500 in Phase 2 Trial, RBC Says

Edgewise Therapeutics' management strongly believes that atrial fibrillation reported by some patients in a phase 2 study was not driven by EDG-7500 as there is no correlation between the cases and higher exposure to the drug, RBC Capital Markets said in a note on Wednesday.

The biopharmaceutical company reported Wednesday "positive" results for the phase 2 trial evaluating EDG-7500 in patients with obstructive or nonobstructive hypertrophic cardiomyopathy and said the most frequent adverse events were dizziness, upper respiratory tract infection and atrial fibrillation. Almost all of the adverse events were mild to moderate in severity, Edgewise said.

RBC analysts said they still recognize a potential risk that atrial fibrillation could be drug-related, but added they believe future data sets including 12-week data due in H2 "should help provide evidence that '7500 is not a driver of afib."

The firm has an outperform, speculative risk rating on the stock and cut its price target to $52 from $56.

Shares were down over 12% in recent trading.

### 相關股票

- [Edgewise Therapeutics (EWTX.US)](https://longbridge.com/zh-HK/quote/EWTX.US.md)

## 相關資訊與研究

- [Edgewise Therapeutics Grants Stock Options to New Employees](https://longbridge.com/zh-HK/news/271516638.md)
- [Edgewise Therapeutics Provides Corporate Updates And Highlights Priorities For 2026](https://longbridge.com/zh-HK/news/272416909.md)
- [Edgewise Therapeutics: Advancing EDG-7500 in Hypertrophic Cardiomyopathy Underpins Buy Rating and Future Value Catalysts](https://longbridge.com/zh-HK/news/270854030.md)
- [Edgewise Therapeutics: Differentiated EDG-7500 Profile, Late-Stage Cardiology Catalyst, and Expanding Pipeline Support Buy Rating](https://longbridge.com/zh-HK/news/270743072.md)
- [Edgewise Therapeutics Completes Key Renal Study for EDG-7500, Setting Up Next Steps for Investors](https://longbridge.com/zh-HK/news/278917336.md)